[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 196, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 64, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": 1794634, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael A. Jacobsen", "age": 65, "title": "Chief Accounting Officer, VP of Finance & Treasurer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 518597, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter B. Cancelmo J.D.", "age": 44, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": 503236, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pamela Pierce Palmer M.D., Ph.D.", "age": 60, "title": "Co-Founder", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 66, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 55, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 64, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 53, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Grauer M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 5, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.52, "open": 4.58, "dayLow": 4.32, "dayHigh": 4.7, "regularMarketPreviousClose": 4.52, "regularMarketOpen": 4.58, "regularMarketDayLow": 4.32, "regularMarketDayHigh": 4.7, "beta": 1.373, "forwardPE": -2.4606743, "volume": 442908, "regularMarketVolume": 442908, "averageVolume": 678442, "averageVolume10days": 439070, "averageDailyVolume10Day": 439070, "bid": 4.32, "ask": 4.82, "bidSize": 2200, "askSize": 1000, "marketCap": 275350912, "fiftyTwoWeekLow": 0.92, "fiftyTwoWeekHigh": 7.8, "fiftyDayAverage": 3.8128, "twoHundredDayAverage": 3.6742, "currency": "USD", "enterpriseValue": 431338848, "floatShares": 56633635, "sharesOutstanding": 62865500, "sharesShort": 13831362, "sharesShortPriorMonth": 13817208, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.22, "heldPercentInsiders": 0.040359996, "heldPercentInstitutions": 0.39859, "shortRatio": 19.28, "shortPercentOfFloat": 0.2292, "bookValue": -0.222, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -181680992, "trailingEps": -2.89, "forwardEps": -1.78, "pegRatio": -0.02, "lastSplitFactor": "1:1", "lastSplitDate": 1254441600, "enterpriseToEbitda": -2.63, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OMER", "underlyingSymbol": "OMER", "shortName": "Omeros Corporation", "longName": "Omeros Corporation", "firstTradeDateEpochUtc": 1255008600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3f7c487e-99e5-35b0-97bc-8da48930057f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.38, "targetHighPrice": 13.0, "targetLowPrice": 13.0, "targetMeanPrice": 13.0, "targetMedianPrice": 13.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 310310016, "totalCashPerShare": 4.936, "ebitda": -164024992, "totalDebt": 466297984, "quickRatio": 2.155, "currentRatio": 2.387, "returnOnAssets": -0.21684, "freeCashflow": -79752872, "operatingCashflow": 84169000, "financialCurrency": "USD", "trailingPegRatio": null}]